Bruton tyrosine kinase inhibitors in the management of Waldenström macroglobulinemia

Bruton tyrosine kinase (BTK) inhibitors have taken a central role in the management of patients with Waldenström macroglobulinemia and are the only agents approved by the Food and Drug Administration (FDA) to treat these patients. Although associated with high rates of durable responses, unmet needs...

Descripción completa

Detalles Bibliográficos
Autores principales: Castillo, Jorge J., Buske, Christian, Trotman, Judith, Sarosiek, Shayna, Treon, Steven P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2023
Materias:
Critical Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10107762/
https://www.ncbi.nlm.nih.gov/pubmed/36415104
http://dx.doi.org/10.1002/ajh.26788

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10107762/
https://www.ncbi.nlm.nih.gov/pubmed/36415104
http://dx.doi.org/10.1002/ajh.26788

Ejemplares similares